IL4 and Alzheimer disease: In addition, increased frequency of circulating ILC2s in AD has been reported (Mashiko et al., 2017), and patients with AD who have a high percentage of ILC2s in their peripheral blood have been reported to respond better to IL-4/13 inhibitors such as dupilumab (Imai et al., 2021).